What is Claimed is:

1. A medicament for preventive and/or therapeutic treatment of Alzheimer's disease which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein A represents hydrogen atom or acetyl group,
E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is ① a fused polycyclic heteroaryl group wherein the ring which binds directly to −CONH− group in the formula (I) is a benzene ring, ② unsubstituted thiazol-2-yl group, or ③ unsubstituted benzothiazol-2-yl group is excluded,
ring Z represents an arene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined above and the group represented by formula −CONH−E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined above and the group represented by formula −CONH−E wherein E has the same meaning as that defined above.

2. A medicament for preventive and/or therapeutic treatment of epilepsy which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the general formula (I) according to claim 1 and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof.

3. The medicament according to claim 1 or 2, wherein A is a hydrogen atom.

4. The medicament according to any one of claims 1 to 3, wherein ring Z is a C_6 to C_{10} arene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula −CONH−E wherein E

has the same meaning as that defined in the general formula (I), or a 5 to 10-membered heteroarene which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —CONH—E wherein E has the same meaning as that defined in the general formula (I).

5. The medicament according to claim 4, wherein ring Z is a benzene ring which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —CONH—E wherein E has the same meaning as that defined in the general formula (I), or a naphthalene ring which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —CONH—E wherein E has the same meaning as that defined in the general formula (I).

6. The medicament according to claim 5, wherein ring Z is a benzene ring which is substituted with halogen atom(s) in addition to the group represented by formula —O—A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula —CONH—E wherein E has the same meaning as that defined in the general formula (I).

7. The medicament according to claim 5, wherein ring Z is a naphthalene ring.

8. The medicament according to any one of claims 1 to 7, wherein E is a 2,5-di-substituted phenyl group or a 3,5-di-substituted phenyl group.

9. The medicament according to claim 8, wherein E is a 2,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, or a 3,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group.

10. The medicament according to claim 9, wherein E is 3,5-bis(trifluoromethyl)phenyl group.

11. The medicament according to any one of claims 1 to 7, wherein E is a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is ① a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, ② unsubstituted thiazol-2-yl group, or ③ unsubstituted

benzothiazol-2-yl group is excluded.

12. The medicament according to claim 11, wherein E is a 5-membered monocyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is unsubstituted thiazol-2-yl group is excluded.